LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PRTA
Prothena Corporation plc
There isn't enough reported data to score PRTA yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
PRTA's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PRTA PE Valuation
PRTA has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PRTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PRTA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PRTA on earnings quality, reporting a profit while its opponent remains loss making.
PRTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.47 | +$4.72 |
| Q2 2026 | -$0.83 | +$4.78 |
| Q1 2026 | -$2.81 | -$0.76 |
| Q4 2025 | -$4.53 | -$2.26 |
| Q3 2025 | -$5.19 | -$2.75 |
| Q2 2025 | -$5.61 | -$4.65 |
| Q1 2025 | -$2.05 | +$1.16 |
| Q4 2024 | -$2.27 | +$0.49 |
PRTA is still losing money, but far less than before: $0.47 per share over the past year, against $5.61 at its worst in mid-2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PRTA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PRTA on profitability, with a higher operating margin.
PRTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $620K | -74% |
| Q2 2026 | $1M | -77% |
| Q1 2026 | $51.1M | +1706% |
| Q4 2025 | $21K | -99% |
| Q3 2025 | $2.4M | +149% |
| Q2 2025 | $4.4M | -97% |
| Q1 2025 | $2.8M | +5556% |
| Q4 2024 | $2.1M | +572% |
PRTA's revenue is growing: $620,000 last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3036% | -1369 points |
| Q2 2026 | -2089% | -175 points |
| Q1 2026 | 59% | +2378 points |
| Q4 2025 | -115252% | -112196 points |
| Q3 2025 | -1666% | +5191 points |
| Q2 2025 | -1914% | -1959 points |
| Q1 2025 | -2319% | +160737 points |
| Q4 2024 | -3057% | +21790 points |
PRTA's operating margin was −3036% last quarter, down 1369 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PRTA on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12M | +$28.6M |
| Q2 2026 | -$25M | +$21.3M |
| Q1 2026 | $28.9M | +$82.2M |
| Q4 2025 | -$23.3M | +$24.5M |
| Q3 2025 | -$40.6M | +$4.6M |
| Q2 2025 | -$46.3M | -390% |
| Q1 2025 | -$53.4M | +$19.7M |
| Q4 2024 | -$47.8M | +$3.3M |
PRTA has burned cash in most quarters: −$31M over the past year, against −$188M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PRTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -708K shares |
| 1 year | -4.4% | -2.4M shares |
| 3 years | -11% | -6.6M shares |
| 5 years | +0.5% | +232K shares |
| Available history | +29% | +11.6M shares |
PRTA has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.3M |
| Q2 2026 | $15.6M |
| Q1 2026 | $6.9M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PRTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -8.1x | Net Cash |
| Q4 2021 | -7.9x | Net Cash |
| Q3 2021 | -7.9x | Net Cash |
PRTA has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PRTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 20.5 | Neutral |
PRTA's weekly RSI is 44 (neutral) and its Stochastic is 21 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PRTA PE vs Healthcare Sector
| Metric | PRTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PRTA has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PRTA on trend strength, trading above more of its moving averages.
PRTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.34 | 1.3% below |
| 20 week MA | $8.74 | 5.8% below |
| 50 week MA | $9.26 | 11% below |
| 100 week MA | $9.67 | 15% below |
| 200 week MA | $23.8 | 65% below |
PRTA is in a downtrend: it's below all five of its weekly moving averages, and 65% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PRTA on returns for 2026, with the stronger performance.
PRTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.0 | $13.2 | -17% |
| 2021 | $13.2 | $48.4 | +265% |
| 2022 | $48.4 | $57.8 | +19% |
| 2023 | $57.8 | $36.3 | -37% |
| 2024 | $36.3 | $15.1 | -58% |
| 2025 | $15.1 | $9.54 | -37% |
| 2026 YTD | $9.54 | $8.23 | -14% |
PRTA has finished three years in a row lower, and it's down 14% so far in 2026.